Trial Profile
A Phase II Study of Inotuzumab Ozogamicin Followed by Blinatumomab for Ph-Negative CD22-Positive B-Lineage Acute Lymphoblastic Leukemia in Newly Diagnosed Older Adults or Adults With Relapsed or Refractory Disease
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 15 Apr 2024
Price :
$35
*
At a glance
- Drugs Blinatumomab (Primary) ; Inotuzumab ozogamicin (Primary)
- Indications Precursor B-cell lymphoblastic leukaemia-lymphoma
- Focus Therapeutic Use
- 30 Jan 2024 Planned End Date changed from 1 Feb 2024 to 1 Feb 2025.
- 30 Jan 2024 Planned primary completion date changed from 1 Feb 2024 to 1 Feb 2025.
- 17 Nov 2023 Status changed from suspended to recruiting.